[go: up one dir, main page]

KR950032636A - 리포펩티드 유도체, 이의 제조방법 및 이의 용도 - Google Patents

리포펩티드 유도체, 이의 제조방법 및 이의 용도 Download PDF

Info

Publication number
KR950032636A
KR950032636A KR1019950006642A KR19950006642A KR950032636A KR 950032636 A KR950032636 A KR 950032636A KR 1019950006642 A KR1019950006642 A KR 1019950006642A KR 19950006642 A KR19950006642 A KR 19950006642A KR 950032636 A KR950032636 A KR 950032636A
Authority
KR
South Korea
Prior art keywords
formula
radicals
lipopeptide
compound
aliphatic acyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
KR1019950006642A
Other languages
English (en)
Other versions
KR100360129B1 (ko
Inventor
라트렐 루돌프
볼만 테오도르
발마이어 홀거
함만 페터
이제르트 디터
Original Assignee
차우너, 루츠
훽스트 아크티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 차우너, 루츠, 훽스트 아크티엔게젤샤프트 filed Critical 차우너, 루츠
Publication of KR950032636A publication Critical patent/KR950032636A/ko
Application granted granted Critical
Publication of KR100360129B1 publication Critical patent/KR100360129B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

본 발명은 하기 일반식(Ⅰ)의 리포펩티드 유도체, 세균 감염에 대해 효과적이고 상기 리포펩티드 유도체를 함유하는 약제학적 생성물, 상기 리포텝티드 유도체 및 약제학적 생성물을 제조하는 방법 및 세균 감염 억제용 상기 리포펩티드 유도체의 용도에 관한 것이다.
상기 식에서, R1은 OH 또는 NH2이고, R2는 C8-C22-아실 라디칼이다.

Description

리포펩티드 유도체, 이의 제조방법 및 이의 용도
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (8)

  1. 하기 일반식(Ⅰ)의 리포텝티드 A1437 유도체 및 약제학적으로 허용되는 이의 염.
    상기 식에서, R1은 OH 또는 NH2이고, R2는 페닐, 사이클로알킬 그룹 또는 산소에 의해 차단될 수 있는 직쇄 또는 측쇄, 포화 또는 불포화 지방족 C8-C22-아실 라디칼이다.
  2. 제1항에 있어서, R2가 포화 지방족 아실 라디칼 CH₃(CH₂)nCO, 측쇄 포화 지방족 아실 라디칼, 바람직하게는 (CH₃)₂CH(CH₂)nCO 또는 CH₃CH₂CH(CH₃)(CH₂)nCO, 이중 결합 하나가 트란스 또는 시스형일 수 있는 이중 결합을 하나 이상 함유할 수 있는 불포화 지방족 아실 라디칼, 바람직하게는 H₂C=CH(CH₂)NCO, (CH₃)₂CH(CH₂)nCH=CH(CH₂)nCO, CH₃(CH₂CH=CH)n(CH₂)NCO, CH₃(CH₂)|nCH= CH(CH₂)nCH=CH(CH₂)nCO, CH₃(CH₂)nCH-CH-CO, CH₃(CH₂)nCH=CH(CH₂)|nCO 또는 H(CH₂C(CH₃)=CH(CH₂)nCO, 하나 이상의 삼중결합을 갖는 불포화 지방족 라디칼, 바람직하게는 HC≡C(CH2)nCO, CH3(CH2)nC≡C(CH2)nCO, CH3(CH2)nC≡C-C≡C(CH2)nCO, 페닐 또는 사이클로알킬 라디칼에 의해 차단된 지방족 아실 라디칼, 바람직하게는 C6H5(CH2)nCO, 산소에 의해 차단된 아실 라디칼, 바람직하게는이고, n이 0 내지 20의 정수인 리포텝티드 유도체.
  3. 제1항에 있어서, R1이 OH 또는 NH2이고, R2가 직쇄 또는 측쇄 C12-C|15-아실 라디칼, 바람직하게는 테트라데카노일, 트리데카노일, 12-메틸트리데카노일, 하나 이상의 이중 또는 삼중 결합을 갖는 불포화 C12-C18-아실 라디칼, 바람직하게는 시스-10-펜타데세노일, 트란스-9-헥사데세노일 또는 H(CH2-C(CH3)=CHCH2)3CO 또는 1 내지 3개의 페닐 라디칼에 의해 및/또는 산소에 의해 추가로 차단된 지방족 아실 라디칼, 바람직하게는
    (여기서, n은 0 내지 8의 정수이다)인 리포펩티드 유도체.
  4. 제1항에 있어서, R1이 OH 또는 NH2이고, R2가 3개의 페닐 그룹에 의해 차단된 지방족 아실 라디칼, 바람직하게는(여기서, n은 0 내지 2의 정수이다)인 리포펩티드 유도체.
  5. 하기 일반식(Ⅱ)의 화합물을 하기 일반식(Ⅲ)의 카복실산 또는 카보닐 그룹이 활성화된 상기 카복실산의 유도체와 반응시킴을 특징으로 하여 하기 일반식(Ⅰ)의 화합물을 제조하는 방법.
    상기 식에서, R1및 R2는 제1항에서 정의 한 바와 같고, R3는 펩티드 화학으로부터 공지된 아미노 보호그룹, 바람직하게는 3급-부톡시카보닐(BOC), 벤질옥시카보닐(Z, Cbz), 플루오레닐메톡시카보닐(Fmoc) 또는 알릴옥시카보닐(Alloc)보호그룹이다.
  6. 약제로서 사용하기 위한 제1항에 따른 일반식(Ⅰ)의 리포펩티드 유도체.
  7. 제1항에 따른 일반식(Ⅰ)의 리포펩티드 유도체 및 약제학적 부형제를 함유하는 약제.
  8. 세균감염에 대한 약제를 제조하기 위한 제1항에 따른 일반식(Ⅰ)의 리포펩티드 유도체의 용도.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019950006642A 1994-03-30 1995-03-28 리포펩티드유도체,이의제조방법및이를포함하는약제학적조성물 Expired - Fee Related KR100360129B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP4411025.1 1994-03-30
DE4411025A DE4411025A1 (de) 1994-03-30 1994-03-30 Lipopeptid-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung

Publications (2)

Publication Number Publication Date
KR950032636A true KR950032636A (ko) 1995-12-22
KR100360129B1 KR100360129B1 (ko) 2003-03-26

Family

ID=6514230

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950006642A Expired - Fee Related KR100360129B1 (ko) 1994-03-30 1995-03-28 리포펩티드유도체,이의제조방법및이를포함하는약제학적조성물

Country Status (24)

Country Link
US (1) US5629288A (ko)
EP (1) EP0688789B1 (ko)
JP (1) JP3653119B2 (ko)
KR (1) KR100360129B1 (ko)
CN (1) CN1111640A (ko)
AT (1) ATE219499T1 (ko)
AU (1) AU696566B2 (ko)
CA (1) CA2145826C (ko)
CZ (1) CZ287158B6 (ko)
DE (2) DE4411025A1 (ko)
DK (1) DK0688789T3 (ko)
ES (1) ES2178657T3 (ko)
FI (1) FI951468A7 (ko)
HU (1) HU218286B (ko)
IL (1) IL113160A (ko)
MA (1) MA23490A1 (ko)
NO (1) NO951198L (ko)
NZ (1) NZ270828A (ko)
OA (1) OA10142A (ko)
PL (1) PL180274B1 (ko)
PT (1) PT688789E (ko)
RU (1) RU2141970C1 (ko)
TW (1) TW336939B (ko)
ZA (1) ZA952555B (ko)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965524A (en) * 1989-07-07 1999-10-12 Peptide Technologies Corporation Analogs of viscosin and uses thereof
TW455591B (en) * 1993-06-08 2001-09-21 Hoechst Ag Lipopeptides from actinoplanes sp. with pharmacological action, process for their production and the use thereof
DE4411025A1 (de) * 1994-03-30 1995-10-05 Hoechst Ag Lipopeptid-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung
US6406880B1 (en) * 1997-05-02 2002-06-18 Integrated Research Technology, Llc Betaines as adjuvants to susceptibility testing and antimicrobial therapy
US7067500B2 (en) * 1997-05-02 2006-06-27 Integrated Research Technology, Llc Betaines as adjuvants to susceptibility testing and antimicrobial therapy
WO1999020651A1 (en) * 1997-10-21 1999-04-29 Sankyo Company, Limited Novel antifungal compounds
DE19807972A1 (de) * 1998-02-25 1999-08-26 Hoechst Marion Roussel De Gmbh Lipopeptidantibiotika-Calciumsalze, Verfahren zu ihrer Herstellung und Verwendung
AU3837600A (en) * 1999-04-16 2000-11-02 Sankyo Company Limited Novel antifungal compounds
EP2298790A1 (en) 1999-12-15 2011-03-23 Cubist Pharmaceuticals, Inc. Daptomycin analogs as antibacterial agents
EP1240182A2 (en) * 1999-12-15 2002-09-18 Cubist Pharmaceuticals, Inc. Daptomycin analogs and their use as antibacterial agents
KR20020063228A (ko) * 1999-12-15 2002-08-01 큐비스트 파마슈티컬즈 인코포레이티드 항균제로서 리포펩티드
US6696412B1 (en) 2000-01-20 2004-02-24 Cubist Pharmaceuticals, Inc. High purity lipopeptides, Lipopeptide micelles and processes for preparing same
US6511962B1 (en) * 2000-07-17 2003-01-28 Micrologix Biotech Inc. Derivatives of laspartomycin and preparation and use thereof
US6737403B2 (en) 2000-07-17 2004-05-18 Micrologix Biotech Inc. Derivatives of laspartomycin and preparation and use thereof
US6750199B2 (en) 2000-07-17 2004-06-15 Micrologix Biotech Inc. Antimicrobial sulfonamide derivatives of lipopeptide antibiotics
AU7893301A (en) * 2000-07-17 2002-01-30 Intrabiotics Pharmaceuticals Antimicrobial sulfonamide derivatives of lipopeptide antibiotics
IL156394A0 (en) 2000-12-18 2004-01-04 Cubist Pharm Inc Methods for preparing purified lipopeptides
US20060014674A1 (en) 2000-12-18 2006-01-19 Dennis Keith Methods for preparing purified lipopeptides
EP1423137B1 (en) * 2001-08-06 2009-04-29 Cubist Pharmaceuticals, Inc. Lipopeptide stereoisomers, methods for preparing same, and useful intermediates
JP4402463B2 (ja) * 2002-01-03 2010-01-20 マイジェニックス インコーポレイテッド リポペプチド抗生物質のＤａｂ９誘導体およびそれを製造および使用する方法
CA2530063A1 (en) * 2003-06-26 2005-01-06 Migenix Inc. Compositions of lipopeptide antibiotic derivatives and methods of use thereof
US8420602B2 (en) * 2004-09-14 2013-04-16 Landon C. G. Miller Endocannabinoid conjugate and a pharmaceutical composition for treatment of neuronal disorders
US7795207B2 (en) 2005-11-21 2010-09-14 Harald Labischinski Lipopeptide compositions
DE102005056194A1 (de) * 2005-11-21 2007-07-12 Combinature Biopharm Ag Neue Lipopeptid Zusammensetzungen
US20080057047A1 (en) * 2005-11-29 2008-03-06 Benedikt Sas Use of bacillus amyloliquefaciens PB6 for the prophylaxis or treatment of gastrointestinal and immuno-related diseases
TWI409077B (zh) * 2006-04-18 2013-09-21 Piramal Life Sciences Ltd 新穎抗菌化合物
US8299795B2 (en) * 2007-02-19 2012-10-30 Schlumberger Technology Corporation Independently excitable resistivity units
GB0821540D0 (en) 2008-11-25 2008-12-31 Merlion Pharmaceuticals Pte Ltd Lipopeptide compounds and their use
RU2512396C2 (ru) * 2008-12-22 2014-04-10 Кьюбист Фармасьютикалз, Инк. Новые противобактериальные средства для лечения грамположительных инфекций
DK2504353T4 (da) 2009-11-23 2023-11-20 Cubist Pharmaceuticals Llc Lipopeptidsammensætninger og tilsvarende fremgangsmåder
CN103554230B (zh) * 2013-09-18 2015-07-22 福建省微生物研究所 一种安福霉素类化合物及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8005121A (nl) * 1979-09-20 1981-03-24 Erba Farmitalia Biologisch actieve peptiden.
CA1337758C (en) * 1988-04-11 1995-12-19 Eli Lilly And Company Peptide antibiotics
US5049546A (en) * 1990-03-19 1991-09-17 Merck & Co., Inc. Antibiotic agents
US5306708A (en) * 1990-12-19 1994-04-26 Merck & Co., Inc. Antibiotic agent
TW455591B (en) * 1993-06-08 2001-09-21 Hoechst Ag Lipopeptides from actinoplanes sp. with pharmacological action, process for their production and the use thereof
DE4411025A1 (de) * 1994-03-30 1995-10-05 Hoechst Ag Lipopeptid-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung

Also Published As

Publication number Publication date
AU1611095A (en) 1995-10-12
CA2145826C (en) 2008-01-08
AU696566B2 (en) 1998-09-10
DK0688789T3 (da) 2002-10-14
DE4411025A1 (de) 1995-10-05
HUT71584A (en) 1995-12-28
HK1012017A1 (en) 1999-07-23
PL180274B1 (pl) 2001-01-31
US5629288A (en) 1997-05-13
MA23490A1 (fr) 1995-10-01
JP3653119B2 (ja) 2005-05-25
KR100360129B1 (ko) 2003-03-26
CZ77995A3 (en) 1995-10-18
NO951198D0 (no) 1995-03-29
NZ270828A (en) 1996-10-28
FI951468L (fi) 1995-10-01
FI951468A7 (fi) 1995-10-01
EP0688789A1 (de) 1995-12-27
JPH07278186A (ja) 1995-10-24
EP0688789B1 (de) 2002-06-19
IL113160A (en) 1999-04-11
ZA952555B (en) 1995-12-21
RU95106362A (ru) 1996-12-27
TW336939B (en) 1998-07-21
PL307914A1 (en) 1995-10-02
IL113160A0 (en) 1995-06-29
HU218286B (en) 2000-07-28
ATE219499T1 (de) 2002-07-15
RU2141970C1 (ru) 1999-11-27
NO951198L (no) 1995-10-02
CA2145826A1 (en) 1995-10-01
FI951468A0 (fi) 1995-03-28
CZ287158B6 (en) 2000-10-11
PT688789E (pt) 2002-11-29
ES2178657T3 (es) 2003-01-01
DE59510246D1 (de) 2002-07-25
OA10142A (fr) 1996-12-18
CN1111640A (zh) 1995-11-15

Similar Documents

Publication Publication Date Title
KR950032636A (ko) 리포펩티드 유도체, 이의 제조방법 및 이의 용도
KR970042553A (ko) 캠프토테신 유도체
YU9301A (sh) Peptidi kao inhibitori hepatitisa c
KR890000494A (ko) 메틸아미노 질소상에서 치환된 스타우로스포린 유도체
RU96101161A (ru) Новые пептидные производные
HUT61780A (en) Process for producing new peptides and pharmaceutical compositions comprising same as active ingredient
KR960703411A (ko) 1-데아미노-8-d-아르기닌 바소프레신의 제조 방법
IL105795A0 (en) Cyclopeptides and their use as absorption promoters when applied to the mucosa
KR910002899A (ko) 혈조절 펩타이드
WO2001062775A3 (en) Novel antiarrhythmic peptides
KR970006312A (ko) 개선된 내용성을 갖는 제약 활성의 β-아미노산
KR900018140A (ko) 레닌 억제제로서 유용한 아미노 치환 복소환식 화합물
ATE125548T1 (de) Peptide.
KR920701244A (ko) 심실 펩티드 유도체
DE60318663D1 (de) Verfahren zur Herstellung optisch aktiver Aminoalkohole
GB992957A (en) New decapeptides and their manufacture
GB1462493A (en) Trypsin inhibitors and process for the production thereof
KR890007752A (ko) 빈크리스틴-함유 생성물
RU95122178A (ru) Синтетические аглюкодальбагептидные антибиотики
KR960702475A (ko) 합성 아글루코달바헵티드 항생제(Synthetic Aglucodalbaheptide Antibiotics)
EP0312158A3 (en) Tetrapeptide renin inhibitors having novel c-terminal amino acid amide
ATE102953T1 (de) Retro-inverso-thrymopentin-analoge, verfahren zu deren herstellung und deren verwendung fuer die zubereitung von pharmazeutischen zusammensetzungen.
EP0331756A4 (en) Agents for prophylaxis and treatment of thrombopenia
KR950011464A (ko) 비가역적 에이치아이브이(hiv) 프로테아제 억제제
TH16235A (th) อนุพันธ์ที่ละลายน้ำได้ของแคมป์โทเธซิน

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20051026

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20051026

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000